Clinical trial NCT03034135: Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Official title: A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Glioblastoma
Lead sponsor: Cantex Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2017-01-27
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed GBM (WHO grade IV).
* The subject must have completed RT with concurrent TMZ at least 12 weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent TMZ.
* Experienced first unequivocal progression of tumor by magnetic resonance imaging (MRI) \[as assessed via Radiologic Assessment in Neuro-Oncology (RANO) criteria within 3 months from the last dose of TMZ.
* Karnofsky performance status (KPS) of at least 60%.
* Willing to remain abstinent from consuming alcohol.
* Recovered from the toxic effects of prior therapy to \< grade 2 toxicity per NCI CTCAE prior to study registration (except lymphopenia).
* Meets laboratory criteria for the following parameters: ANC, platelets, hemoglobin, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, BUN and creatinine.
* 11. Females of childbearing potential must be willing to use an acceptable method of birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.

Exclusion Criteria:

* Radiographic evidence of leptomeningeal dissemination, gliomatosis cerebri, infratentorial tumor, or disease at sites remote from the supratentorial brain.
* Enrolled in another clinical trial testing a novel therapy or drug within the past 4 weeks.
* Received more than one course of radiation therapy or more than a total dose of 75 Gy.
* History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.
* Treatment with the following medications are contraindicated with DSF: metronidazole, isoniazid, dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertraline, tindazole, tizanidine, atazanavir.
* Fever within 3 days prior to study enrollment.
* Active or severe hepatic or renal disease.
* Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE
* History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to glioblastoma, corticosteroid, or anti-epileptic medications.
* History of Wilson's disease.
* History of hemochromatosis.
* Pregnant or breastfeeding.

Primary outcomes:
measure: Objective Response Rate
timeFrame: 6 months
Secondary outcomes:
measure: Progression Free Survival
timeFrame: 6 months
measure: Overall Survival
timeFrame: 6 months and 12 months
measure: Number of Participants With Serious Adverse Events
timeFrame: 14 months
measure: Median Progression Free Survival
timeFrame: 12 months
measure: Median Duration of Overall Survival
timeFrame: 14 months
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: Beaumont Hospital
state: Michigan
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
city: Hackensack
country: United States
facility: John Theurer Cancer Center
state: New Jersey
city: New York
country: United States
facility: Lenox Hill Hospital
state: New York
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
city: Nashville
country: United States
facility: Vanderbilt Ingram Cancer Center
state: Tennessee
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
Study officials:
affiliation: Washington University School of Medicine in St. Louis
name: Jiayi Huang, MD
role: STUDY_CHAIR
References:
citation: Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 2019 May;142(3):537-544. doi: 10.1007/s11060-019-03125-y. Epub 2019 Feb 15.